SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Meta Expands AI Training With Employee Activity Tracking Tools 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SAN DIEGO, May 22, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer of Obalon, and William Plovanic, Chief Financial Officer of Obalon, will present at the following investor conference:
- UBS Global Healthcare Conference
Tuesday, May 23, 2017, Presentation at 1:00pm EST
Grand Hyatt, New York, NY
Webcast Available at:
https://cc.talkpoint.com/ubsx001/052217a_as/?entity=88_Q55L3I5
Live audio webcasts of the presentation can be accessed through the link above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office: +1 646 517 4220 [email protected]
